The study included stage IIIB/IV NSCLC patients with EGFR common mutations including exon 19 deletion and exon 21 L858R mutation, who had benefited from first-line gefitinib treatment, and followed by further-line chemotherapy. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.